NLS Pharmaceutics AG (NLSP)
Market Cap | 9.98M |
Revenue (ttm) | n/a |
Net Income (ttm) | -15.47M |
Shares Out | 35.67M |
EPS (ttm) | -0.50 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 543,207 |
Open | 0.320 |
Previous Close | 0.301 |
Day's Range | 0.220 - 0.349 |
52-Week Range | 0.220 - 1.600 |
Beta | -0.72 |
Analysts | Hold |
Price Target | n/a |
Earnings Date | May 3, 2024 |
About NLSP
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of AD... [Read more]
Financial Performance
Financial StatementsNews
NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event
ZURICH, SWITZERLAND / ACCESSWIRE / March 14, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discove...
Nasdaq Accepts NLS Pharmaceutics' Plan to Regain Listing Compliance
ZURICH, SWITZERLAND / ACCESSWIRE / March 11, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discove...
NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq
ZÜRICH, SWITZERLAND / ACCESSWIRE / February 23, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the disc...
Notice of Deficiency with Nasdaq Continued Listing Requirements
ZURICH, SWITZERLAND / ACCESSWIRE / January 12, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the disco...
NLS Pharmaceutics CEO Issues Letter to Shareholders
ZURICH, SWITZERLAND / ACCESSWIRE / December 29, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company, focused on the discovery ...
NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.
The option agreement grants NLS Pharmaceutics Ltd. the exclusive option to in-license all of Aexon Labs' assets for the potential treatment of narcolepsy and other neuro-degenerative disorders, and al...
NLS Pharmaceutics Announces Election of Additional Board Members
Professor Claudio L. A. Bassetti, MD, is the Chair, Neurology Department, Inselspital, Bern University Hospital and Dean, Medical Faculty, University of Bern, focused on sleep disorders Professor Flor...
NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic Hypersomnia
ZURICH, SWITZERLAND / ACCESSWIRE / November 27, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery a...
NLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge Loan
NLS has executed a non-binding term sheet for licensing of NLS intellectual property NLS has secured an additional bridge loan through insiders to extend cash runway NLS has implemented significant in...
NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification
ZURICH, SWITZERLAND / ACCESSWIRE / October 25, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP,NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and...
NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions
ZURICH, SWITZERLAND / ACCESSWIRE / October 19, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery an...
NLS Pharmaceutics Announces Company Update on Strategic Partnerships
Members of Executive Leadership Team to Discuss Company Update on Strategic Discussions and Timeline of Phase 3, NLS to Webcast its Event Friday, October 20 at 11:00am ET ZURICH, SWITZERLAND / ACCESSW...
NLS Pharmaceutics shares rise as narcolepsy treatment moves to phase 3 studies
Shares of NLS Pharmaceutics Ltd. NLSP, +19.57% gained 12% premarket on Monday after the Swiss clinical-stage biopharma company said it would proceed with phase 3 clinical studies of Mazindol ER, a tre...
NLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol
ZÜRICH, SWITZERLAND / ACCESSWIRE / July 3, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...
NLS Pharmaceutics Releases the Results from its Annual General Meeting
ZURICH, SWITZERLAND / ACCESSWIRE / June 30, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and d...
NLS Pharmaceutics Company Update and Webcast Today Postponed
NLS to Webcast its Event on Thursday, July 6, 2023, at 11:00 am ET ZURICH, SWITERLAND / ACCESSWIRE / June 30, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swis...
CORRECTION FROM SOURCE: NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
Presentation to take place on Tuesday, June 20, 2023, at 10:30AM ET ZURICH, SWITZERLAND / ACCESSWIRE / June 19, 2023 / NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss cl...
NLS Pharmaceutics Announces Company Update Webcast
Members of Executive Leadership Team to Discuss initiation of Phase 3, Pipeline updates, Key Financials, Corporate Development, and the other topics NLS to Webcast its Event Friday, June 30 at 11:00am...
NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
ZURICH, SWITZERLAND / ACCESSWIRE / June 15, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and d...
NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450 and Transporter Mediated Drug-Drug Interaction Studies of Mazindol
Very low risk for drug-drug interactions (DDI) with Mazindol ER based upon results from in vitro metabolism and transporter studies Demonstrated pharmacological differentiation versus currently availa...
NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer
ZÜRICH, SWITZERLAND / ACCESSWIRE / May 8, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery ...
NLS Pharmaceutics Presents Latest Clinical and Preclinical Data at SLEEP 2023
Oral presentation sharing significant phase 2 results of Mazindol ER in Adults with Narcolepsy Type 1 and Type 2 Five abstracts demonstrating NLS focus on and investment in hypersomnia disorders and r...
NLS Pharmaceutics Receives Green Light from the U.S. FDA to Proceed with Phase 3 Clinical Program (AMAZE) for Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy
ZURICH, SWITZERLAND / ACCESSWIRE / May 2, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and dev...
NLS Pharmaceutics Presents Latest Preclinical Pipeline Data at American Society of Clinical Psychopharmacology
ZURICH, SWITZERLAND / ACCESSWIRE / April 25, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discove...
NLS Pharmaceutics Announces Open Label Extension Study Six-Month Data for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy Type 1 and Type 2
Patients treated with Mazindol ER in the randomized Phase 2 trial showed continued improvement after rolling over into the open label extension (OLE) study Patients treated with placebo in the randomi...